SETANAXIB
Setanaxib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against NADPH oxidase 4 and NADPH oxidase 1. In addition, it is known to target cytochrome b-245 heavy chain and SPESP1-NOX5 readthrough.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
8 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Biliary liver cirrhosis | D008105 | — | K74.3 | — | 2 | — | — | — | 2 |
| Cholangitis | D002761 | HP_0030151 | K83.0 | — | 2 | — | — | — | 2 |
| Fibrosis | D005355 | — | — | — | 1 | — | — | — | 1 |
| Idiopathic pulmonary fibrosis | D054990 | — | J84.112 | — | 1 | — | — | — | 1 |
| Pulmonary fibrosis | D011658 | — | — | — | 1 | — | — | — | 1 |
| Diabetic nephropathies | D003928 | EFO_0000401 | — | — | 1 | — | — | — | 1 |
| Albuminuria | D000419 | EFO_0004285 | R80.9 | — | 1 | — | — | — | 1 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 1 | — | — | — | 1 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | 1 | — | — | — | 1 |
| Carcinoma | D002277 | — | C80.0 | — | 1 | — | — | — | 1 |
Show 4 more
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | SETANAXIB |
| INN | setanaxib |
| Description | Setanaxib (development code GKT-831) is an experimental orally bioavailable dual inhibitor of NADPH oxidase isoforms NOX4 and NOX1. Setanaxib is a member of the pyrazolopyridine dione chemical series. The compound is the only specific NOX inhibitor that has entered into clinical trials.
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CN(C)c1cccc(-c2c3c(=O)n(-c4ccccc4Cl)[nH]c3cc(=O)n2C)c1 |
Identifiers
| PDB | — |
| CAS-ID | 1218942-37-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4303187 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 45II35329V (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 872 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use